NEW YORK--(BUSINESS WIRE)--Pluristem Therapeutics Inc. (NasdaqCM:PSTI) (DAX:PJT), a bio-therapeutics company dedicated to the commercialization of non-personalized (allogeneic) cell therapy products for a variety of degenerative, ischemic and autoimmune indications, announced today that the Company’s product, PLX-BMT, is featured in the August issue of the peer-reviewed Journal Expert Opinion on Biological Therapy1. PLX-BMT utilizes the Company’s proprietary PLacental eXpanded (PLX) cells as an alternative to bone marrow transplantation (BMT). PLX cells are mesenchymal stromal cells (MSCs) obtained from human placenta and expanded using Pluristem’s proprietary 3D PluriX™ technology.
